Get the Stockscreener App
9.1712
2.40%
0.2012
Arvinas Inc stock is traded at $9.1712, with a volume of 443.34K.
It is up +2.40% in the last 24 hours and up +14.67% over the past month.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
See More
Previous Close:
$8.97
Open:
$8.91
24h Volume:
443.34K
Relative Volume:
0.54
Market Cap:
$599.59M
Revenue:
$89.40M
Net Income/Loss:
$-221.30M
P/E Ratio:
-2.8164
EPS:
-3.2564
Net Cash Flow:
$-256.90M
1W Performance:
+2.17%
1M Performance:
+14.67%
6M Performance:
-19.71%
1Y Performance:
+29.55%
1-Day Range:
$8.894
$9.26
1-Week Range:
$8.71
$9.26
52-Week Range:
$6.955
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
9.17 | 586.51M | 89.40M | -221.30M | -256.90M | -3.2564 |
VRTX
Vertex Pharmaceuticals Inc
|
514.82 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.67 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
989.02 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.24 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.30 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-25 | Downgrade | Goldman | Neutral → Sell |
| Sep-24-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
D. E. Shaw adjusts Arvinas (ARVN) stake as one entity falls below 5% - Stock Titan
Arvinas (ARVN) Q2 2026 Earnings Call Transcript - AOL.com
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Enterprise value to EBITDA forward of Arvinas, Inc. – NASDAQ:ARVN - TradingView
ARVN Maintains by Evercore ISI Group -- Price Target Lowered to $14.00 - GuruFocus
ARVN Maintained by Citigroup -- Price Target Lowered to $21.00 - GuruFocus
Morgan Stanley Maintains Arvinas(ARVN.US) With Hold Rating, Maintains Target Price $10 - moomoo.com
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $10 to $21 - Moomoo
Arvinas, Inc. Stock 12‑Month Price Target Cut to $13.93, Implies 59% Upside - TradingView
Precision Trading with Arvinas Inc. (ARVN) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX) - The Globe and Mail
Arvinas (NASDAQ:ARVN) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BofA Securities Maintains Arvinas(ARVN.US) With Hold Rating - Moomoo
Arvinas (NASDAQ:ARVN) Upgraded to "Strong-Buy" at Zacks Research - marketbeat.com
Arvinas, Inc. (ARVN) stock price, news, quote and history - Yahoo Finance Australia
HC Wainwright Has Pessimistic Outlook of Arvinas Q3 Earnings - MarketBeat
Arvinas Inc (ARVN) Stock News Today - TradingKey
Analysts Are Bullish on These Healthcare Stocks: Bruker (BRKR), Arvinas Holding Company (ARVN) - The Globe and Mail
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
H.C. Wainwright Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Arvinas Holding Earnings Call: PROTAC Milestone and Outlook - The Globe and Mail
Transcript: Arvinas Q2 2026 Earnings Conference Call - Sahm
Arvinas (NASDAQ:ARVN) Trading Down 7.8% on Analyst Downgrade - MarketBeat
ARVN Maintains Neutral Rating by Wedbush -- Price Target Raised to $12 - GuruFocus
Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit - TradingKey
BTIG reiterates Arvinas stock Buy rating on pipeline execution By Investing.com - Investing.com UK
Arvinas, Inc. Stock 12‑Month Price Target Cut to $14.85, Implies 84% Upside - TradingView
Arvinas, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
ARVN Reiterated by BTIG -- Price Target Maintained at $18.00 - GuruFocus
Arvinas (NASDAQ: ARVN) posts $169.4M profit on VEPPANU and Rigel deals - Stock Titan
ARVINAS, INC. 2026: Revenue $249.7M, EPS $2.58— 10-Q Summary - TradingView
BTIG reiterates Arvinas stock Buy rating on pipeline execution - Investing.com
BTIG Research Reiterates Buy Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
Arvinas' (ARVN) "Equal Weight" Rating Reaffirmed at Wells Fargo & Company - marketbeat.com
Earnings call transcript: Arvinas Q2 2026 profit beat lifts outlook - Investing.com
Wedbush Adjusts Price Target on Arvinas to $12 From $11, Maintains Neutral Rating - finance.yahoo.com
Arvinas (NASDAQ:ARVN) Trading 14.8% Higher Following Better-Than-Expected Earnings - marketbeat.com
Arvinas Q2 Earnings Call Highlights - MarketBeat
Arvinas (NASDAQ:ARVN) Releases Earnings Results, Beats Expectations By $2.95 EPS - MarketBeat
Arvinas Inc reports results for the quarter ended June 30Earnings Summary - tradingview.com
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
ARVINAS ($ARVN) Releases Q2 2026 Earnings - Quiver Quantitative
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Arvinas reports $249.7M Q2 revenue, $169.4M net income and guidance into H2 2028 - TradingView
BRIEF-Arvinas Q2 Operating Income USD 164.1 Million - TradingView
ARVN: FDA approval, major out-licensing, and pipeline focus drive strong Q2 results and outlook - TradingView
Earnings To Watch: Arvinas Inc (ARVN) Q2 2026 -- GF Value Sees 34% Upside - Yahoo Finance
Arvinas (ARVN) Projected to Announce Quarterly Earnings on Wednesday - marketbeat.com
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026 - The Manila Times
Arvinas to give corporate update during Aug. 4 webcast - Stock Titan
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):